Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial.

IF 3 3区医学 Q1 PEDIATRICS

European Journal of Pediatrics Pub Date : 2024-11-20 DOI:10.1007/s00431-024-05861-4

Nermeen Ellakkany, Hesham Abdel-Hady, Ahmed Mahfouz Eita, Youssef M Mosaad, Ahmed Megahed

{"title":"Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial.","authors":"Nermeen Ellakkany, Hesham Abdel-Hady, Ahmed Mahfouz Eita, Youssef M Mosaad, Ahmed Megahed","doi":"10.1007/s00431-024-05861-4","DOIUrl":null,"url":null,"abstract":"Objects: Preterm infants are at an increased risk of developing feeding intolerance (FI) due to the functional immaturity of their gastrointestinal tract. Recent studies and meta-analyses have shown a significant role of bovine lactoferrin (LF) in the management of feeding intolerance and sepsis. This study aimed to assess the effects of oral bovine LF supplementation on FI in preterm infants (26-34 weeks gestational age) and its effect on intestinal permeability measured by serum zonulin concentrations.Methods: A randomized controlled double-blind interventional pilot study was conducted in the Neonatal Intensive Care Unit (NICU) of Mansoura University. Sixty preterm neonates with FI were included in the study and were randomly assigned into two groups: lactoferrin group (100 mg/day bovine LF for 4 weeks or until discharge) and control group.Results: The time needed to achieve full enteral feeding of sixty preterm infants (26-34 weeks gestational age) (9 vs. 15 days, P = 0.001) was significantly shorter and serum zonulin concentrations at end of the trial or discharge (3.38 vs. 5.49 ng/ml, P = 0.04) were significantly lower in the lactoferrin group compared with the control group.Conclusion: Oral bovine lactoferrin given to preterm infants (26-34 weeks gestational age) is associated with improvement of feeding intolerance and decreased intestinal permeability.Trial registration: This study was registered at clinical trials.gov with ID (NCT04738058) at 2 March 2021.","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 1","pages":"30"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00431-024-05861-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objects: Preterm infants are at an increased risk of developing feeding intolerance (FI) due to the functional immaturity of their gastrointestinal tract. Recent studies and meta-analyses have shown a significant role of bovine lactoferrin (LF) in the management of feeding intolerance and sepsis. This study aimed to assess the effects of oral bovine LF supplementation on FI in preterm infants (26-34 weeks gestational age) and its effect on intestinal permeability measured by serum zonulin concentrations.

Methods: A randomized controlled double-blind interventional pilot study was conducted in the Neonatal Intensive Care Unit (NICU) of Mansoura University. Sixty preterm neonates with FI were included in the study and were randomly assigned into two groups: lactoferrin group (100 mg/day bovine LF for 4 weeks or until discharge) and control group.

Results: The time needed to achieve full enteral feeding of sixty preterm infants (26-34 weeks gestational age) (9 vs. 15 days, P = 0.001) was significantly shorter and serum zonulin concentrations at end of the trial or discharge (3.38 vs. 5.49 ng/ml, P = 0.04) were significantly lower in the lactoferrin group compared with the control group.

Conclusion: Oral bovine lactoferrin given to preterm infants (26-34 weeks gestational age) is associated with improvement of feeding intolerance and decreased intestinal permeability.

Trial registration: This study was registered at clinical trials.gov with ID (NCT04738058) at 2 March 2021.

查看原文本刊更多论文

牛乳铁蛋白对早产儿喂养不耐受和肠道渗透性的影响：随机对照试验。

目标：早产儿由于胃肠道功能不成熟，患喂养不耐受（FI）的风险较高。最近的研究和荟萃分析表明，牛乳铁蛋白（LF）在治疗喂养不耐受和败血症方面具有重要作用。本研究旨在评估口服牛乳铁蛋白补充剂对早产儿（胎龄 26-34 周）喂养不耐受的影响及其对以血清zonulin 浓度衡量的肠道通透性的影响：在曼苏尔大学新生儿重症监护室（NICU）开展了一项随机对照双盲干预试验研究。研究将 60 名患有 FI 的早产新生儿随机分为两组：乳铁蛋白组（100 毫克/天的牛乳铁蛋白，持续 4 周或直至出院）和对照组：结果：与对照组相比，乳铁蛋白组60例早产儿（胎龄26-34周）实现完全肠内喂养所需的时间（9天 vs. 15天，P = 0.001）明显缩短，试验结束或出院时血清佐纳林浓度（3.38 ng/ml vs. 5.49 ng/ml，P = 0.04）明显降低：结论：早产儿（胎龄26-34周）口服牛乳铁蛋白可改善喂养不耐受，降低肠道渗透性：本研究于 2021 年 3 月 2 日在 clinical trials.gov 上注册，注册号为 (NCT04738058)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pediatrics 医学-小儿科

CiteScore

5.90

自引率

2.80%

发文量

367

审稿时长

3-6 weeks

期刊介绍： The European Journal of Pediatrics (EJPE) is a leading peer-reviewed medical journal which covers the entire field of pediatrics. The editors encourage authors to submit original articles, reviews, short communications, and correspondence on all relevant themes and topics. EJPE is particularly committed to the publication of articles on important new clinical research that will have an immediate impact on clinical pediatric practice. The editorial office very much welcomes ideas for publications, whether individual articles or article series, that fit this goal and is always willing to address inquiries from authors regarding potential submissions. Invited review articles on clinical pediatrics that provide comprehensive coverage of a subject of importance are also regularly commissioned. The short publication time reflects both the commitment of the editors and publishers and their passion for new developments in the field of pediatrics. EJPE is active on social media (@EurJPediatrics) and we invite you to participate. EJPE is the official journal of the European Academy of Paediatrics (EAP) and publishes guidelines and statements in cooperation with the EAP.